CareDx, Inc. Files Form 144
CareDx, Inc. filed a Form 144 with the SEC on November 5, 2026, as reported by StreetInsider.
Stocks · News reference
BTIG Raises CareDx Price Target to $92
BTIG maintained a "Buy" rating on CareDx and increased its price target from $81 to $92.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
CareDx raised its 2026 revenue guidance to $520M-$530M and adjusted EBITDA outlook to $90M-$100M, driven by strong transplant testing demand with volumes up 21% to 50,750. The company's specialty oncology business (NavDx) contributed $12.5M in Q3 revenues with 37% year-over-year growth. Management is preparing new molecular diagnostics AlloHeme and HistoMap Kidney for 2027 commercialization while targeting higher reimbursement rates per test.
CareDx Announces Publication of Third KOAR Analysis in Transplantation
CareDx, Inc. announced the publication of a new analysis from its Kidney Allograft Outcomes AlloSure Registry (KOAR) in the journal Transplantation.
H.C. Wainwright Raises CareDx Price Target
Analyst Yi Chen of H.C. Wainwright maintained a 'Neutral' rating on CareDx while increasing the price target from $46 to $90.
Ark Invest Reduces Holdings in CareDx
Ark Invest reported a reduction in its position in CareDx, Inc. (CDNA), selling approximately $4.4 million worth of shares.
Why CareDx Stock Soared Today
CareDx stock surged over 22% after reporting strong Q3 2026 earnings with 39% revenue growth to $139 million, driven by a 65% jump in testing services revenue and 51% increase in testing volumes. The company raised its full-year revenue guidance to $525 million (38% growth) and boosted adjusted EBITDA targets to $90-100 million, reflecting growing clinical interest in precision medicine diagnostics.